Even in the era of molecular targeting therapy combinations, continuation of molecular targeting drugs after tumor progression, so-called “beyond progression”, is not recommended [30], and analysis using data of sequential administration of hormonal therapy that is the basis of ER+ HER2− breast cancer treatment is important. Here, ESR1 is linked to neoplasm.